Published in Clin Cancer Res on October 15, 2011
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol (2012) 1.32
Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol (2012) 1.30
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 1.25
Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol (2012) 1.21
Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol (2013) 1.18
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol (2015) 1.17
Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol (2012) 1.12
Antibody-drug conjugates-an emerging class of cancer treatment. Br J Cancer (2016) 1.11
Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep (2015) 1.03
ADME of antibody-maytansinoid conjugates. AAPS J (2012) 1.03
Methods for site-specific drug conjugation to antibodies. MAbs (2014) 1.00
B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol (2013) 0.97
CD19 as an attractive target for antibody-based therapy. MAbs (2012) 0.96
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res (2013) 0.94
Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Leukemia (2013) 0.92
Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs (2012) 0.90
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? Oncologist (2012) 0.88
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells. PLoS One (2014) 0.86
Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies. Curr Hematol Malig Rep (2013) 0.86
Nature and importance of follicular lymphoma precursors. Haematologica (2014) 0.85
A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS One (2013) 0.85
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Protein Sci (2015) 0.84
Advances in the treatment of hematologic malignancies using immunoconjugates. Blood (2014) 0.83
Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res (2013) 0.79
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials. J Ocul Pharmacol Ther (2015) 0.79
Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells. Mediterr J Hematol Infect Dis (2015) 0.78
Antibody therapy for pediatric leukemia. Front Oncol (2014) 0.78
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol (2014) 0.78
7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. MAbs (2012) 0.76
Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line. Avicenna J Med Biotechnol (2015) 0.75
Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther (2017) 0.75
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci (2005) 1.55
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol (2003) 1.21
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res (2005) 1.18
Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res (2007) 1.17
Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci (2004) 1.17
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol (2012) 1.17
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol (2006) 1.11
Near wins prolong gambling on a video lottery terminal. J Gambl Stud (2003) 1.11
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res (2010) 1.11
Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 1.08
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther (2003) 1.07
ADME of antibody-maytansinoid conjugates. AAPS J (2012) 1.03
Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci (2007) 1.02
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem (2011) 1.01
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.99
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs (2011) 0.99
Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther (2009) 0.93
Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res (2007) 0.91
Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng (2005) 0.90
Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. Pharm Res (2005) 0.90
The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res (2005) 0.88
Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem Pharmacol (2004) 0.86
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2013) 0.85
Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release (2005) 0.85
Amoeboid Microglial Cells and not Astrocytes Synthesize TNF-alpha in Swiss Mouse Brain Cell Cultures. Eur J Neurosci (1990) 0.85
Human FGF-1 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters. J Gene Med (2004) 0.84
Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis (2014) 0.84
Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem (2012) 0.83
Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone. J Med Chem (2011) 0.82
Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res (2007) 0.82
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res (2004) 0.81
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. Anal Biochem (2005) 0.80
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol (2008) 0.79
The use of direct cDNA selection to rapidly and effectively identify genes in the fungus Aspergillus fumigatus. Fungal Genet Biol (2002) 0.79
Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci (2005) 0.79
2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Res (2002) 0.79
Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L). Blood (2002) 0.78
Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J Ocul Pharmacol Ther (2010) 0.77
[Prevention of fungal infections related to the water supply in French hospitals: proposal for standardization of methods]. Presse Med (2008) 0.76
Estimation of the differential pressure at renal artery stenoses. Magn Reson Med (2004) 0.75
Efficient gene regulation by PPAR gamma and thiazolidinediones in skeletal muscle and heart. Mol Ther (2002) 0.75
[Pain assessment in children by triage emergency nurses]. Soins Pediatr Pueric (2011) 0.75
Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett (2003) 0.75